- Home
- PMN vs DRCT Comparison
PMN vs DRCT Comparison
Compare PMN & DRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMN
- DRCT
- Stock Information
- Founded
- PMN 2004
- DRCT 2018
- Country
- PMN Canada
- DRCT United States
- Employees
- PMN N/A
- DRCT N/A
- Industry
- PMN Pharmaceuticals and Biotechnology
- DRCT Computer Software: Programming Data Processing
- Sector
- PMN Health Care
- DRCT Technology
- Exchange
- PMN Nasdaq
- DRCT Nasdaq
- Market Cap
- PMN 17.0M
- DRCT 16.7M
- IPO Year
- PMN N/A
- DRCT 2022
- Fundamental
- Price
- PMN $0.49
- DRCT $0.55
- Analyst Decision
- PMN Strong Buy
- DRCT Strong Buy
- Analyst Count
- PMN 2
- DRCT 1
- Target Price
- PMN $4.50
- DRCT $6.00
- AVG Volume (30 Days)
- PMN 42.3K
- DRCT 157.6K
- Earning Date
- PMN 08-07-2025
- DRCT 05-06-2025
- Dividend Yield
- PMN N/A
- DRCT N/A
- EPS Growth
- PMN N/A
- DRCT N/A
- EPS
- PMN N/A
- DRCT N/A
- Revenue
- PMN N/A
- DRCT $48,170,000.00
- Revenue This Year
- PMN N/A
- DRCT $50.71
- Revenue Next Year
- PMN N/A
- DRCT $26.31
- P/E Ratio
- PMN N/A
- DRCT N/A
- Revenue Growth
- PMN N/A
- DRCT N/A
- 52 Week Low
- PMN $0.47
- DRCT $0.44
- 52 Week High
- PMN $2.37
- DRCT $6.59
- Technical
- Relative Strength Index (RSI)
- PMN 43.83
- DRCT 51.91
- Support Level
- PMN $0.48
- DRCT $0.51
- Resistance Level
- PMN $0.53
- DRCT $0.56
- Average True Range (ATR)
- PMN 0.03
- DRCT 0.03
- MACD
- PMN 0.00
- DRCT 0.01
- Stochastic Oscillator
- PMN 21.29
- DRCT 70.27
About PMN ProMIS Neurosciences Inc. (ON)
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.
About DRCT Direct Digital Holdings Inc.
Direct Digital Holdings Inc is an end-to-end, full-service programmatic advertising platform primarily focused on providing advertising technology, data-driven campaign optimization, and other solutions to underserved and less efficient markets on both the buy-side and sell-side of the digital advertising ecosystem. The company operates two reportable segments: sell-side advertising, which includes the results of Colossus Media, and buy-side advertising, which includes the results of Orange 142 and Huddled Masses. All of the company's revenues are attributed to the United States.